HLA-DRW4 IN 91% OF JEWISH PEMPHIGUS VULGARIS PATIENTS
M.S. Park(University of California, Los Angeles), J. L. Tiwari(University of California, Los Angeles), A. R. Ahmed(Nirma University), Paul I. Terasaki(University of California, Los Angeles)
Cited by 119
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
|New England Journal of Medicine|2006|452
Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris.
|Proceedings of the National Academy of Sciences|1995|249
Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.
|Proceedings of the National Academy of Sciences|1995|203
Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris.
|Proceedings of the National Academy of Sciences|1991|170